ArticleACS central science2026
Design of Epitope-Focused Vaccines via Epitope Cleavage.
Article in ACS central science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The design of epitope-focused immunogens that steer serum antibody responses toward epitopes targeted by broadly neutralizing antibodies (bnAbs) is a promising approach to develop broad-spectrum vaccines against pathogens with high genetic variability. Here, we introduce a strategy called epitope cleavage, which involves "cleaving" an epitope to steer antibodies away from it onto other regions of an antigen. We demonstrated the utility of epitope cleavage using two independent approaches: circular permutation and proteolytic cleavage. We first designed a sarbecovirus vaccine candidate by circularly permuting the receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; we next designed broad Ebolavirus immunogens by inserting the TEV protease cleavage site into the glycan cap of Ebola glycoprotein (GP) for site-specific epitope cleavage. By cleaving variable regions on each antigen, both the circular permuted RBD and cleaved GPs elicited antibodies with enhanced cross-reactivity to related viruses compared to unmodified antigen and exhibited a reduction in antibody responses toward the "cleaved" epitope. Our results present epitope cleavage as a vaccine design strategy that redirects antibody responses without compromising immunogenicity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.